Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $52.4444.

SEPN has been the topic of a number of research analyst reports. Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. HC Wainwright lifted their price objective on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Guggenheim boosted their price objective on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their target price on Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th.

Septerna Stock Down 1.7%

NASDAQ:SEPN opened at $38.86 on Wednesday. The firm has a market cap of $1.81 billion, a PE ratio of -71.96 and a beta of 2.30. Septerna has a 12 month low of $14.35 and a 12 month high of $51.10. The company’s 50-day moving average price is $37.98 and its two-hundred day moving average price is $31.67.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. On average, research analysts expect that Septerna will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $35.18, for a total transaction of $76,622.04. Following the sale, the insider owned 793 shares of the company’s stock, valued at $27,897.74. This represents a 73.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel Long sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at $3,423,590.12. The trade was a 13.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 52,178 shares of company stock worth $2,064,804 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new position in Septerna in the 1st quarter worth approximately $906,000. TRV GP V LLC acquired a new position in Septerna during the 2nd quarter worth $208,160,143. TRV GP VI LLC bought a new position in Septerna in the 2nd quarter valued at $141,048,460. First Light Asset Management LLC boosted its position in Septerna by 18.0% in the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after buying an additional 112,049 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Septerna in the 1st quarter valued at $21,334,000.

Septerna Company Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Orthosteric Ligand Discovery platform to study GPCRs in their native cellular environments and identify small-molecule compounds that can modulate these receptors.